SEARCH

SEARCH BY CITATION

References

  • Anichtchik O. V., Kaslin J., Peitsaro N., Scheinin M. and Panula P. (2004) Neurochemical and behavioural changes in zebrafish Danio rerio after systemic administration of 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurochem. 88, 443453.
  • Anichtchik O., Sallinen V., Peitsaro N. and Panula P. (2006) Distinct structure and activity of monoamine oxidase in the brain of zebrafish (Danio rerio). J. Comp. Neurol. 498, 593610.
  • Beal M. F. (2001) Experimental models of Parkinson’s disease. Nat. Rev. Neurosci. 2, 325334.
  • Bretaud S., Lee S. and Guo S. (2004) Sensitivity of zebrafish to environmental toxins implicated in Parkinson’s disease. Neurotoxicol. Teratol. 26, 857864.
  • Brustein E., Saint-Amant L., Buss R. R., Chong M., McDearmid J. R. and Drapeau P. (2003) Steps during the development of the zebrafish locomotor network. J. Physiol. Paris 97, 7786.
  • Di Porzio U., Zuddas A., Cosenza-Murphy D. B. and Barker J. L. (1990) Early appearance of tyrosine hydroxylase immunoreactive cells in the mesencephalon of mouse embryos. Int. J. Dev. Neurosci. 8, 523532.
  • Guo S., Wilson S. W., Cooke S., Chitnis A. B., Driever W. and Rosenthal A. (1999) Mutations in the zebrafish unmask shared regulatory pathways controlling the development of catecholaminergic neurons. Dev. Biol. 208, 473487.
  • Heikkila R. E., Manzino L., Cabbat F. S. and Duvoisin R. C. (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311, 467469.
  • Holzschuh J., Ryu S., Aberger F. and Driever W. (2001) Dopamine transporter expression distinguishes dopaminergic neurons from other catecholaminergic neurons in the developing zebrafish embryo. Mech. Dev. 101, 237243.
  • Hornykiewicz O. and Kish S. J. (1987) Biochemical pathophysiology of Parkinson’s disease. Adv. Neurol. 45, 1934.
  • Hsu C. H., Wen Z. H., Lin C. S. and Chakraborty C. (2007) The zebrafish model: use in studying cellular mechanisms for a spectrum of clinical disease entities. Curr. Neurovasc Res. 4, 111120.
  • Kalsbeek A., Voorn P. and Bujis R. (1992) Development of dopamine-containing systems in the CNS, in Ontogeny of Transmitters and Peptides in the CNS (BjörklundA., HökfeltT. and TohyamaM., eds), pp. 63112. Elsevier, Amsterdam, The Netherlands.
  • Kaslin J. and Panula P. (2001) Comparative anatomy of the histaminergic and other aminergic systems in zebrafish (Danio rerio). J. Comp. Neurol. 440, 342377.
  • Kish S. J., Tong J., Hornykiewicz O., Rajput A., Chang L. J., Guttman M. and Furukawa Y. (2008) Preferential loss of serotonin markers in caudate versus putamen in Parkinson’s disease. Brain 131(Pt 1), 120131.
  • Lam C. S., Korzh V. and Strahle U. (2005) Zebrafish embryos are susceptible to the dopaminergic neurotoxin MPTP. Eur. J. Neurosci. 21, 17581762.
  • Manso M. J., Becerra M., Molist P., Rodriguez-Moldes I. and Anadon R. (1993) Distribution and development of catecholaminergic neurons in the brain of the brown trout. A tyrosine hydroxylase immunohistochemical study. J. Hirnforsch. 34, 239260.
  • McKinley E. T., Baranowski T. C., Blavo D. O., Cato C., Doan T. N. and Rubinstein A. L. (2005) Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons. Brain Res. Mol. Brain Res. 141, 128137.
  • Nakamura S. and Vincent S. R. (1986) Histochemistry of MPTP oxidation in the rat brain: sites of synthesis of the parkinsonism-inducing toxin MPP+. Neurosci. Lett. 65, 321325.
  • Nicklas W. J., Vyas I. and Heikkila R. E. (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36, 25032508.
  • Nussbaum R. L. and Ellis C. E. (2003) Alzheimer’s disease and Parkinson’s disease. N. Engl. J. Med. 348, 13561364.
  • Panula P., Airaksinen M. S., Pirvola U. and Kotilainen E. (1990) A histamine-containing neuronal system in human brain. Neuroscience 34, 127132.
  • Panula P., Sallinen V., Sundvik M., Kolehmainen J., Torkko V., Tiittula A., Moshnyakov M. and Podlasz P. (2006) Modulatory Neurotransmitter Systems and Behavior: Towards Zebrafish Models of Neurodegenerative Diseases. Zebrafish 3, 235247.
  • Perry T. L., Yong V. W., Jones K., Wall R. A., Clavier R. M., Foulks J. G. and Wright J. M. (1985) Effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its metabolite, N-methyl-4-phenylpyridinium ion, on dopaminergic nigrostriatal neurons in the mouse. Neurosci. Lett. 58, 321326.
  • Przedborski S., Jackson-Lewis V., Naini A. B., Jakowec M., Petzinger G., Miller R. and Akram M. (2001) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76, 12651274.
  • Rink E. and Wullimann M. F. (2001) The teleostean (zebrafish) dopaminergic system ascending to the subpallium (striatum) is located in the basal diencephalon (posterior tuberculum). Brain Res. 889, 316330.
  • Rink E. and Wullimann M. F. (2002) Development of the catecholaminergic system in the early zebrafish brain: an immunohistochemical study. Brain Res. Dev. Brain Res. 137, 89100.
  • Setini A., Pierucci F., Senatori O. and Nicotra A. (2005) Molecular characterization of monoamine oxidase in zebrafish (Danio rerio). Comp. Biochem. Physiol. B Biochem. Mol. Biol. 140, 153161.
  • Streisinger G., Walker C., Dower N., Knauber D. and Singer F. (1981) Production of clones of homozygous diploid zebra fish (Brachydanio rerio). Nature 291, 293296.
  • Wen L., Wei W., Gu W., Huang P., Ren X., Zhang Z., Zhu Z., Lin S. and Zhang B. (2008) Visualization of monoaminergic neurons and neurotoxicity of MPTP in live transgenic zebrafish. Dev. Biol. 314, 8492.
  • Westerfield M. (1995) The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish (Danio Rerio), pp. 3.13.25. University of Oregon Press, Eugene, OR.
  • Wullimann M. F., Rupp B. and Reichert H. (1996) Neuroanatomy of the Zebrafish Brain: A Topological Atlas, pp. 1144. Birkhauser Verlag, Basel.